Kenvue Initiates Quarterly Cash Dividend
20.7.2023 13:23:00 EEST | Business Wire | Press release
Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, today announced that its Board of Directors has declared a dividend payable in the third quarter of 2023 of $0.20 per share on the Company’s common stock.
“The decision by our Board of Directors to declare a dividend further underscores the confidence we have in the strength of our portfolio of iconic brands to drive profitable growth and durable cash flow generation over the long term,” said Thibaut Mongon, Chief Executive Officer and Director. “The dividend is an important component of our disciplined capital allocation strategy and our plan to deliver sustained value creation for all of our stockholders.”
The third quarter dividend is payable on September 7, 2023, to shareholders of record as of the close of business on August 28, 2023.
Second Quarter 2023 Financial Results and Conference Call Information
Kenvue also today announced its financial results for the second quarter ending July 2, 2023. As previously announced, company will host a conference call and webcast at 7:30 a.m. Eastern Time to discuss its second quarter results. The conference call can be accessed by dialing 877-407-8835 from the U.S. or 201-689-8779 from international locations. A live webcast of the conference call will be available at https://investors.kenvue.com. A replay will be available approximately two hours after the live event.
About Kenvue
Kenvue is the world’s largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand Adhesive Bandages, Johnson’s®, Listerine®, Neutrogena®, and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we believe in the extraordinary power of everyday care and our teams work every day to put that power in consumers’ hands and earn a place in their hearts and homes. Learn more at www.kenvue.com.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance. Forward-looking statements may be identified by the use of words such as “plans,” “expects,” “will,” “anticipates,” “estimates” and other words of similar meaning. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kenvue and its affiliates.
A list and descriptions of risks, uncertainties and other factors can be found in Kenvue’s filings with the Securities and Exchange Commission, including its registration statement on Form S-1 and subsequent Quarterly Reports on Form 10-Q and other filings, available at www.kenvue.com or on request from Kenvue. Kenvue and its affiliates undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or developments or otherwise.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230720695902/en/
Contact information
Investor Relations:
Tina Romani
Kenvue_IR@Kenvue.com
Media Relations:
Melissa Witt
media@kenvue.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
France Becomes First Official Participant at Expo 2030 Riyadh25.8.2026 20:40:00 EEST | Press release
France is the first country to officially sign its Participation Contract for Expo 2030 Riyadh, a major milestone in its preparations and growing international momentum. The signing took place on the sidelines of the visit to France by His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince and Prime Minister. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260825634516/en/ The ceremony in Paris was attended by H.H. Prince Faisal bin Farhan Al Saud, Minister of Foreign Affairs of the Kingdom of Saudi Arabia, and Dimitri S. Kerkentzes, Secretary General of the BIE. The Participation Contract was signed by Talal Al-Marri, Chief Executive Officer of Expo 2030 Riyadh, and Jacques Maire, Chairman of the Compagnie Française des Expositions (COFREX). The agreement formally establishes France’s participation in Expo 2030 Riyadh, providing the framework for its presence throughout the six-month event. It spec
Saudi Arabia and BIE Sign See Agreement for Expo 2030 Riyadh, Advancing Framework for International Participation25.8.2026 20:17:00 EEST | Press release
The Kingdom of Saudi Arabia and the Bureau International des Expositions (BIE) have signed the See Agreement for Expo 2030 Riyadh, formally establishing the legal and administrative framework that will support Official Participants throughout their journey to the World Expo. The signing took place on the sidelines of the visit to France by His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince and Prime Minister. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260825419959/en/ H.H. Prince Faisal bin Farhan Al Saud, Minister of Foreign Affairs of the Kingdom of Saudi Arabia, and Dimitri S. Kerkentzes, Secretary General of the BIE, at the ceremony. The ceremony was attended by H.H. Prince Faisal bin Farhan Al Saud, Minister of Foreign Affairs of the Kingdom of Saudi Arabia, Dimitri S. Kerkentzes, Secretary General of the BIE, and Talal Al-Marri, CEO of Expo 2030 Riyadh. The See Agreement sets out the
The LYCRA Company Reimagines the Trade Show Experience at Intertextile25.8.2026 19:11:00 EEST | Press release
The LYCRA Company, a global leader in fiber and technology solutions for the apparel industry, is reimagining the trade show experience at Intertextile Shanghai Apparel Fabrics Autumn Edition, which opened today in China. Building on the success of last year's ALL IN concept, the company has expanded its co-creation vision into a 356-square-meter Lifestyle District featuring partners Jingzili New Material, JYT Textile, Lianxingfa Knitting, and Trend Textile. The district is part of a larger 895-square-meter pavilion showcasing a total of 19 co-exhibitors. Together, they demonstrate how innovations in fiber, fabric, and garments can be combined to create compelling solutions for both work and play. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260821281698/en/ The LYCRA Company expands its co-creation vision through an immersive Lifestyle District at Intertextile Shanghai. “The apparel industry is built on creativity, and gr
BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA25.8.2026 17:40:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of adult patients with unresectable locally advanced or metastatic HER2-positive (HER2+) gastric, gastroesophageal junction, or esophageal adenocarcinoma (GEA). The approval is supported by results from the Phase 3 HERIZON-GEA-01 trial, which were published in The New England Journal of Medicine earlier this year. GEA, which includes adenocarcinomas of the stomach, gastroesophageal junction and esophagus, remains an area of substantial unmet need in the United States, with more than 31,000 new stomach cancer cases diagnosed each year.1 Approximately 20% of patients with GEA have HER2+ disease, a subtype that has historically been difficult to treat.2,3,
Gatik Raises $200 Million; Series D Led by QIA and KDT as Demand for Driverless Commercial Freight Accelerates25.8.2026 16:00:00 EEST | Press release
Gatik, the leader in autonomous trucking, today announced $200 million in financing as demand accelerates for driverless commercial freight across Fortune 50 retail, grocery and CPG supply chains. The Series D round was led by Qatar Investment Authority (QIA) and Koch Disruptive Technologies (KDT), with participation from Millennium Management, ARK Invest, Intact Private Capital and others. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260825490075/en/ Gatik Announces Series D round Gatik has built one of the most commercially advanced businesses in autonomous freight, with more than $600 million in contracted revenue, 85,000 fully driverless orders completed, and 99% on-time delivery across its operations. Its trucks move goods across high-frequency regional networks between distribution centers and stores, giving customers a reliable way to add capacity, improve service levels and keep products moving. “This round, led by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
